Want To Fly In China‘s New Normal? Learn From Merck
Executive Summary
Many multinationals are banking on novel drug products to capture China’s new growth spurt as it transforms to care centered on innovative therapies, although this could be a hard sell given the largely private pay nature of the market for such products. Q2 China growth at Merck & Co. however flew through the roof with the aid of a suite of newly launched products. So what made it a shining star?
You may also be interested in...
Ready To Ride Next Growth Wave In China? Remember Five Keys
As China enters a new growth spur for the health sector, underscored by faster product approvals, annual reimbursement coverage and strong demand for high-quality treatments, strategic planning and meticulous execution are more important than ever if companies want to win in the world's second-largest pharma market, says a new report.
Lost In Translation? New Zoonotic Virus Naming Gets China's Largest Physician Platform In Trouble
China's largest physician portal DXY has been banned from posting on a major social media platform after naming a new zoonotic virus after the place where it originated.
Lost In Translation? New Zoonotic Virus Naming Gets China's Largest Physician Platform In Trouble
China's largest physician portal DXY has been banned from posting on a major social media platform after naming a new zoonotic virus after the place where it originated.